Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols

Leukemia. 2013 Sep;27(9):1936-9. doi: 10.1038/leu.2013.92. Epub 2013 Mar 29.

Authors

I Ofverholm, A N Tran, M Heyman, V Zachariadis, M Nordenskjöld, A Nordgren, G Barbany

PMID: 23538749
DOI: 10.1038/leu.2013.92

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Child
Child, Preschool
Chromosome Aberrations
Female
Gene Amplification*
Gene Deletion*
Humans
Ikaros Transcription Factor / genetics*
Infant
Karyotype
Male
PAX5 Transcription Factor / genetics*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality
Prognosis

Substances

IKZF1 protein, human
PAX5 Transcription Factor
PAX5 protein, human
Ikaros Transcription Factor